Barclays upgrades Sandoz to “overweight,” sees 20% upside on biosimilar ’runway’

Investing.com Gold reports: Barclays upgrades Sandoz to “overweight,” sees 20% upside on biosimilar ’runway’. Full body text was unavailable at ingest time, so this brief is based on headline context.